Skip to main content
Equibles
KMTS logo

KMTS · Kestra Medical Technologies, Ltd. · Metrics

Track KMTS — free

Use KMTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KMTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.76 +0.44 (+1.55%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.71B
Shares
59.56M
Volume · Oct 23 357.23K Avg daily vol (3M) 358.16K

KMTS metrics

86 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$28.76
Market cap
$1.71B

Price action

20 metrics
Price change (1W)
+5.6%
Price change (30D)
+11.6%
Price change (3M)
+36.6%
Price change (6M)
+28.1%
Price change (YTD)
+8.4%
Price change (1Y)
+12.0%
Trailing year
Price change (5Y)
—
52-week high
$29.37
52-week low
$17.87
Change from 52-week high
-2.1%
Change from 52-week low
+60.9%
Annualized volatility
64.0%
Annualized volatility (3M)
60.4%
Beta
1.7
RSI (14D)
56.4
Price vs SMA 50
+8.6%
Price vs SMA 200
+21.6%
Avg volume (3M)
358,163
Relative volume
1.0
Average dollar volume
$9.38M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
59.56M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
14.6×
reciprocal yield 6.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
15.8×
reciprocal yield 6.3%
P / book
7.6
reciprocal yield 13.2%
FCF yield
-7.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.9×
reciprocal yield 7.2%
EV / revenue historical average (5Y)
13.9×
reciprocal yield 7.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-14

Profitability

9 metrics
Gross margin
53.9%
Operating margin
-134.5%
Trailing 12 months
Net margin
-140.4%
Gross profit (TTM)
$57.51M
Operating profit (TTM)
−$143.52M
Net income (TTM)
−$149.87M
Trailing 12 months
Diluted EPS (TTM)
$-2.68
FCF margin
-115.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.90
Gross profit per diluted share (TTM)
$1.02
Operating profit per diluted share (TTM)
$-2.56
EBITDA per diluted share (TTM)
$-2.39
Net income per diluted share (TTM)
$-2.67
Operating cash flow per diluted share (TTM)
$-1.56
Free cash flow per diluted share (TTM)
$-2.18
Capital expenditures per diluted share (TTM)
$0.62
R&D per diluted share (TTM)
$0.40
Stock compensation per diluted share (TTM)
$0.69
Book value per share
$4.45

Growth

11 metrics
Revenue growth YoY
+59.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$106.73M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-67.4%
Return on assets
-43.1%
Debt / equity
0.3
Current ratio
4.7
EBITDA (TTM)
−$134.18M
Free cash flow (TTM)
−$122.78M
Quick ratio
4.7
Interest coverage
-19.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$126.42M
Latest balance sheet
Cash & equivalents
$68.56M
Total assets
$347.36M
Total debt
$72.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$87.72M
Capital expenditures (TTM)
$35.06M
R&D (TTM)
$22.28M
SG&A (TTM)
$178.75M
Stock compensation (TTM)
$38.58M
R&D / revenue
20.9%
Stock compensation / revenue
36.2%

Ownership (13F)

9 metrics
13F filers
108
13F filer change QoQ
+5
Institutional ownership
98.6%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.1%
Holder tenure
5.5
Price vs estimated holder cost
+13.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.5%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 7.3 days to cover
Days to cover
7.3d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$6.00M
Insider-sentiment score
6 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1877184 CUSIP G52441105 13F (30d) 11 filings 11 filers Visit website Investor relations